From OpenAI to Eli Lilly how Chai Discovery is changing AI drug development

City: San Francisco: Chai Discovery is a company that uses AI to help make new medicines. It started in 2024 and is growing really fast. In just over a year, Chai has raised hundreds of millions of dollars from many important investors. They recently shared they got $130 million more, making the company worth $1.3 billion.

Chai Discovery just made a deal with Eli Lilly, one of the biggest drug companies. Eli Lilly will use a special computer program called Chai-2 to help develop new medicines. Chai-2 is good at designing antibodies, which are needed to fight diseases. They hope their program will help create new drugs faster.

This is an exciting time for Chai. The news about their deal came right before Eli Lilly announced a new project with Nvidia to open an AI lab in San Francisco. This lab will mix big data and science to speed up making new medicines.

Some people are not so sure these new technologies will work well since drug development can be really hard. But many others are hopeful. Elena Viboch is from a company called General Catalyst, and she believes that those who team up with Chai will see success. She says that companies who partner with Chai will quickly start getting new medicines tested.

Aliza Apple from Eli Lilly is also confident. She thinks by using Chai’s technology with Lilly’s knowledge, they can create better medicines faster for patients.

Chai Discovery may be young, but its story began about six years ago when its founders talked with Sam Altman, the CEO of OpenAI. One founder, Josh Meier, used to work at OpenAI. After he left, Altman asked another founder, Jack Dent, if Meier wanted to start a new company focused on proteins.

Dent and Meier waited until they felt ready to start their company. In 2024, they reached out to Altman again and began Chai Discovery. OpenAI was one of their first investors and even gave them office space to work.

Now, just more than a year later, Chai is excited about its new partnership with Eli Lilly. Dent believes their fast growth comes from having a very talented team. They are creating new models that are special and not just using common ones you find online.

Viboch believes Chai is ready to move forward. She sees great potential in using these new models for drug discovery. While drugs still need testing, she thinks adopting these technologies will speed up developing new medicines and help make types of drugs that are usually hard to create.